The only provider of allergen-monitoring tools in India and South East Asia, Indoor Biotechnologies is a global leader in environmental allergen-detection systems. Its services are sorely needed, with the number of allergy sufferers crossing 350 million in India alone.
Due to rapid urbanization and the pollution that comes with it, India has been recording an increasing number of patients with allergic reactions, who suffer from asthma. Incubated in 2015, Indoor Biotechnologies India uses cutting edge technologies to develop allergen monitoring for dust, air, food, diagnostic and clinical preparations. It designs the monitoring tools to be used in one go, which results in an economically viable process, enabling it to target a wider customer base.
“Improving patient care through research, education and by developing cutting-edge technologies that serve our clients and customers worldwide, is what our company primarily focuses on”, say Indoor Biotechnologies founders Dr. Sivasankar Baalasubramanian, Dr. James Hindley & Dr. Martin Chapman.
The bioplex reader is used for developing assays on the luminex xMAP technology. The technology allows multiple ELISAs to be integrated into one assay.
...what makes Indoor Biotech different from its peers? The answer is, its solid focus on the identification and monitoring of allergens...
It was the first company to occupy space at the Bangalore Bioinnovation Centre, a leading bio-cluster with state-of-the-art incubation infrastructure. Indoor Biotechnologies was founded by Dr. Sivasankar Baalasubramanian (India), Dr. James Hindley (UK) & Dr. Martin Chapman (USA). Dr. Balasubramanian and Dr. Hindley both have Ph.D.s in Immunology, from the All India Institute of Medical Sciences (AIIMS) in New Delhi, and the School of Medicine, Cardiff University in the UK, respectively. Dr. Chapman is a former Professor of Medicine and Microbiology at the University of Virginia and a Fellow of the American Academy of Allergy, Asthma, and Immunology.
These distinguished credentials aside, what makes Indoor Biotech different from its peers? The answer is, its solid focus on the identification and monitoring of allergens. This is important because allergens are the main cause of breathing diseases such as asthma. In India, asthma disproportionately affects children in urban areas and also those from lower socio-economic groups, with substandard living conditions. Furthermore, a general dearth of allergen-monitoring tools has led to the absence of regulatory guidelines on monitoring and controlling the usage of allergens present in packaged food products’ ingredients.
Reducing allergy triggers is the first step in controlling the spread of asthma and other related conditions. The company develops products and services pertaining to allergies, asthma, indoor air quality, environmental sciences, and various kinds of allergens, for both consumer and academic requirements.
Soon, Indoor will have a complete technology suite comprising a portfolio of antibodies that can detect allergens in a variety of biological entities and specimens including cats, dogs, mold, food, house dust mites, cockroaches and other allergens.